Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk NMIBC”

89 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 89 results

Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 1,397
Testing effectiveness (Phase 2)Looking for participantsNCT06663137
What this trial is testing

Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

Who this might be right for
Non Muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc. 70
Early research (Phase 1)WithdrawnNCT06816017
What this trial is testing

Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Non-muscle Invasive Bladder Cancer
Hoffmann-La Roche
Testing effectiveness (Phase 2)Study completedNCT04172675
What this trial is testing

Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 107
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc. 190
Large-scale testing (Phase 3)Not Yet RecruitingNCT07207824
What this trial is testing

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBC
Fudan University 182
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07100184
What this trial is testing

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Who this might be right for
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
Peking University First Hospital 30
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Not applicableUnknownNCT05547516
What this trial is testing

Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Who this might be right for
Non-muscle-invasive Bladder Cancer
First Affiliated Hospital Xi'an Jiaotong University 140
Large-scale testing (Phase 3)Looking for participantsNCT06696794
What this trial is testing

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang 180
Testing effectiveness (Phase 2)Looking for participantsNCT06388720
What this trial is testing

The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy

Who this might be right for
Bladder Cancer
National Cancer Center, Korea 82
Post-approval studies (Phase 4)Active Not RecruitingNCT04701151
What this trial is testing

NORTH-REG Dwell-Time Study

Who this might be right for
Side Effect of Drug
Jørgen Bjerggaard Jensen 314
Testing effectiveness (Phase 2)Looking for participantsNCT06378242
What this trial is testing

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd. 24
Not applicableLooking for participantsNCT06287541
What this trial is testing

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Who this might be right for
Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University 428
Early research (Phase 1)WithdrawnNCT04089163
What this trial is testing

Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Who this might be right for
Bladder Cancer
Tocagen Inc.
Early research (Phase 1)Study completedNCT03191578
What this trial is testing

Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®

Who this might be right for
High-Risk Non-Muscle-Invasive Bladder Cancer
Archivel Farma S.L. 44
Large-scale testing (Phase 3)Active Not RecruitingNCT05714202
What this trial is testing

TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

Who this might be right for
Bladder Cancer
Janssen Research & Development, LLC 1,135
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Testing effectiveness (Phase 2)Study completedNCT04387461
What this trial is testing

Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder Cancer
CG Oncology, Inc. 35
Load More Results